{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:44:16Z","timestamp":1792014256860,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with primary cutaneous lymphoma may have substantial impairments in health-related quality of life (HRQoL) and may require referral to specialized radiation oncology centers. The current exploratory baseline analysis assessed patient preferences for quality of life (QoL) versus length of life (LoL), travel distance, and baseline HRQoL before radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Of 130 screened patients, 82\u00a0patients with primary cutaneous lymphoma referred for radiotherapy were enrolled in the prospective S\u2011MISR registry between September 2019 and August 2024. Their QoL-versus-LoL preferences were assessed using the Quality\u2013Quantity Questionnaire. Baseline HRQoL was evaluated using Skindex-29 and EORTC QLQ-C30. Travel distance to the treating radiation oncology department was analyzed overall and by lymphoma subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age was 63\u00a0years (range 34\u201392), and 59\u00a0patients (72%) had advanced-stage disease. Fifty-six patients (68%) had mycosis fungoides (MF), 13\u00a0(16%) had S\u00e9zary syndrome (SS), and 13\u00a0(16%) had other primary cutaneous lymphomas. Overall, 31\u00a0patients (38%) prioritized QoL, 21\u00a0(25%) prioritized LoL, and 30\u00a0(37%) rated both equally. Median travel distance was longest for S\u00e9zary syndrome (201\u202fkm), followed by mycosis fungoides (114\u202fkm) and non-MF\/SS lymphomas (65\u202fkm). Older age and longer travel distance emerged as potential factors associated with QoL preference. Baseline Skindex-29 scores indicated greater HRQoL impairment in MF and SS than in non-MF\/SS lymphomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patient preferences regarding QoL versus LoL vary considerably before radiotherapy. Travel burden may be an important patient-centered factor for treatment planning, shared decision-making, and future prospective radiotherapy studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02615-z","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:44:38Z","timestamp":1792010678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient preferences and travel burden before radiotherapy for primary cutaneous lymphoma: baseline results from the S-MISR registry"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7576-2373","authenticated-orcid":false,"given":"David Rene","family":"Steike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Elsayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Falke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"2615_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/bjd.18089","volume":"182","author":"K Molloy","year":"2020","unstructured":"Molloy\u00a0K, Jonak\u00a0C, Woei-A-Jin\u00a0FJSH et\u00a0al (2020) Characteristics associated with significantly worse quality of life in mycosis fungoides\/S\u00e9zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 182:770\u2013779. https:\/\/doi.org\/10.1111\/bjd.18089","journal-title":"Br J Dermatol"},{"key":"2615_CR2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/jdv.19799","volume":"38","author":"AEC Schirren","year":"2024","unstructured":"Schirren\u00a0AEC, Albrecht\u00a0JD, Melchers\u00a0S et\u00a0al (2024) Health-related quality of life and its influencing factors in patients with primary cutaneous B\u2011cell lymphomas: a multicentric study in 100 patients. JEADV Clin Pract 38:954\u2013966. https:\/\/doi.org\/10.1111\/jdv.19799","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2615_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjd.13732","volume":"173","author":"T Beynon","year":"2015","unstructured":"Beynon\u00a0T, Selman\u00a0L, Radcliffe\u00a0E et\u00a0al (2015) \u2018We had to change to single beds because I itch in the night\u2019: a\u00a0qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T\u2011cell lymphoma. Br J Dermatol 173:83\u201392. https:\/\/doi.org\/10.1111\/bjd.13732","journal-title":"Br J Dermatol"},{"key":"2615_CR4","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/bjd.13583","volume":"172","author":"LE Selman","year":"2015","unstructured":"Selman\u00a0LE, Beynon\u00a0T, Radcliffe\u00a0E et\u00a0al (2015) \u2018We\u2019re all carrying a\u00a0burden that we\u2019re not sharing\u2019: a\u00a0qualitative study of the impact of cutaneous T\u2011cell lymphoma on the family. Br J Dermatol 172:1581\u20131592. https:\/\/doi.org\/10.1111\/bjd.13583","journal-title":"Br J Dermatol"},{"key":"2615_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/ddg.14706","volume":"20","author":"E Dippel","year":"2022","unstructured":"Dippel\u00a0E, Assaf\u00a0C, Becker\u00a0JC et\u00a0al (2022) S2k-Guidelines - Cutaneous lymphomas (ICD 10 C82-C86): Update 2021. J\u00a0Dtsch Dermatol Ges 20:537\u2013554. https:\/\/doi.org\/10.1111\/ddg.14706","journal-title":"J Dtsch Dermatol Ges"},{"key":"2615_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdin.2024.07.002","volume":"17","author":"A Heger","year":"2024","unstructured":"Heger\u00a0A, Elsayad\u00a0K, Kandler\u00a0C et\u00a0al (2024) Health-related quality of life in primary cutaneous B\u2011cell lymphoma following local radiotherapy. JAAD Int 17:53\u201354. https:\/\/doi.org\/10.1016\/j.jdin.2024.07.002","journal-title":"JAAD Int"},{"key":"2615_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e21663","volume":"35","author":"C Castillo","year":"2017","unstructured":"Castillo\u00a0C, Alfonzo\u00a0AL, Camejo\u00a0N et\u00a0al (2017) Impact of measuring quality of life in oncology practice: a prospective study. J\u00a0Clin Oncol 35:e21663. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.e21663","journal-title":"J Clin Oncol"},{"key":"2615_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","volume":"133","author":"R Dummer","year":"2020","unstructured":"Dummer\u00a0R, Prince\u00a0HM, Whittaker\u00a0S et\u00a0al (2020) Patient-reported quality of life in patients with relapsed\/refractory cutaneous T\u2011cell lymphoma: results from the randomised phase III ALCANZA study. Eur J Cancer 133:120\u2013130. https:\/\/doi.org\/10.1016\/j.ejca.2020.04.010","journal-title":"Eur J Cancer"},{"key":"2615_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jaad.2021.03.025","volume":"86","author":"T Nawar","year":"2022","unstructured":"Nawar\u00a0T, Elsayad\u00a0K, M\u00fcller\u00a0EC et\u00a0al (2022) Quality of life in patients with mycosis fungoides and S\u00e9zary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapy. J\u00a0Am Acad Dermatol 86:889\u2013891. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.025","journal-title":"J Am Acad Dermatol"},{"key":"2615_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1365-2133.2008.08992.x","volume":"160","author":"F Sampogna","year":"2009","unstructured":"Sampogna\u00a0F, Frontani\u00a0M, Baliva\u00a0G et\u00a0al (2009) Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol 160:815\u2013822. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08992.x","journal-title":"Br J Dermatol"},{"key":"2615_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/sj.bjc.6601445","volume":"89","author":"CG Koedoot","year":"2003","unstructured":"Koedoot\u00a0CG, de Haan\u00a0RJ, Stiggelbout\u00a0AM et\u00a0al (2003) Palliative chemotherapy or best supportive care? A prospective study explaining patients\u2019 treatment preference and choice. Br J Cancer 89:2219\u20132226. https:\/\/doi.org\/10.1038\/sj.bjc.6601445","journal-title":"Br J Cancer"},{"key":"2615_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJMp1109283","volume":"366","author":"MJ Barry","year":"2012","unstructured":"Barry\u00a0MJ, Edgman-Levitan\u00a0S (2012) Shared decision making - the pinnacle of patient-centered care. N Engl J Med 366:780\u2013781. https:\/\/doi.org\/10.1056\/NEJMp1109283","journal-title":"N Engl J Med"},{"key":"2615_CR13","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1002\/cncr.23968","volume":"113","author":"NJ Meropol","year":"2008","unstructured":"Meropol\u00a0NJ, Egleston\u00a0BL, Buzaglo\u00a0JS et\u00a0al (2008) Cancer patient preferences for quality and length of life. Cancer Cytopathol 113:3459\u20133466. https:\/\/doi.org\/10.1002\/cncr.23968","journal-title":"Cancer"},{"key":"2615_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0272989X9601600211","volume":"16","author":"AM Stiggelbout","year":"1996","unstructured":"Stiggelbout\u00a0AM, de Haes\u00a0JC, Kiebert\u00a0GM et\u00a0al (1996) Tradeoffs between quality and quantity of life: development of the QQ Questionnaire for Cancer Patient Attitudes. Med Decis Making 16:184\u2013192. https:\/\/doi.org\/10.1177\/0272989X9601600211","journal-title":"Med Decis Making"},{"key":"2615_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1159\/000366250","volume":"37","author":"K Laryionava","year":"2014","unstructured":"Laryionava\u00a0K, Sklenarova\u00a0H, Heu\u00dfner\u00a0P et\u00a0al (2014) Cancer patients\u2019 preferences for quantity or quality of life: German translation and validation of the Quality and Quantity Questionnaire. Oncol Res Treat 37:472\u2013478. https:\/\/doi.org\/10.1159\/000366250","journal-title":"Oncol Res Treat"},{"key":"2615_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren\u00a0MM, Lasek\u00a0RJ, Quinn\u00a0LM et\u00a0al (1996) Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J\u00a0Invest Dermatol 107:707\u2013713. https:\/\/doi.org\/10.1111\/1523-1747.ep12365600","journal-title":"J Invest Dermatol"},{"key":"2615_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","volume":"133","author":"MM Chren","year":"1997","unstructured":"Chren\u00a0MM, Lasek\u00a0RJ, Flocke\u00a0SA et\u00a0al (1997) Improved discriminative and evaluative capability of a\u00a0refined version of Skindex, a\u00a0quality-of-life instrument for patients with skin diseases. Arch Dermatol 133:1433\u20131440. https:\/\/doi.org\/10.1001\/archderm.1997.03890470111018","journal-title":"Arch Dermatol"},{"key":"2615_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson\u00a0NK, Ahmedzai\u00a0S, Bergman\u00a0B et\u00a0al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI Cancer Spectr 85:365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"2615_CR19","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen\u00a0EA, Whittaker\u00a0S, Kim\u00a0YH et\u00a0al (2011) Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J\u00a0Clin Oncol 29:2598\u20132607. https:\/\/doi.org\/10.1200\/JCO.2010.32.0630","journal-title":"J Clin Oncol"},{"key":"2615_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/ddg.14044","volume":"18","author":"K Elsayad","year":"2020","unstructured":"Elsayad\u00a0K, Stadler\u00a0R, Steinbrink\u00a0K et\u00a0al (2020) Combined total skin radiotherapy and immune checkpoint inhibitors: a promising potential treatment for mycosis fungoides and S\u00e9zary syndrome. J\u00a0Dtsch Dermatol Ges 18:193\u2013197. https:\/\/doi.org\/10.1111\/ddg.14044","journal-title":"J Dtsch Dermatol Ges"},{"key":"2615_CR21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/jme.10.3.124","volume":"10","author":"KC Calman","year":"1984","unstructured":"Calman\u00a0KC (1984) Quality of life in cancer patients - an hypothesis. J\u00a0Med Ethics 10:124\u2013127. https:\/\/doi.org\/10.1136\/jme.10.3.124","journal-title":"J Med Ethics"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02615-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:44:39Z","timestamp":1792010679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02615-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":21,"alternative-id":["2615"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02615-z","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"5 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.R.\u00a0Steike, K.\u00a0Elsayad, I.\u00a0Falke, C.\u00a0Kandler, and H.T.\u00a0Eich declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed complied with the 1964 Helsinki declaration and its later amendments or comparable ethical standards and were approved by the Medical Association of Westphalia-Lippe (no. 2024-399-f-S).\n                      Human investigations\n                      : All investigators conducted the human research after receiving approval from a\u00a0local ethics committee and in accordance with the principles of the Helsinki declaration. We obtained informed consent from each patient.","order":3,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}}]}}